CT-388vsEcnoglutide

CT-388 is a once-weekly subcutaneous dual GLP-1/GIP receptor agonist, mechanistically similar to tirzepatide but with a distinct molecular structure designed for differentiated pharmacology. Activation of both receptors produces complementary metabolic effects: GLP-1 receptor agonism centrally suppresses appetite through hypothalamic and brainstem signalling, slows gastric emptying, and stimulates glucose-dependent insulin secretion from pancreatic beta cells, while GIP receptor agonism enhances beta-cell insulin response, modulates lipid handling in adipose tissue, and amplifies the central anorectic effect of GLP-1 through distinct hypothalamic neuronal circuits.

The molecule was engineered with a balanced potency profile across the two receptors and incorporates fatty acid acylation that enables strong albumin binding, extending half-life to approximately one week. This pharmacokinetic profile supports once-weekly subcutaneous dosing with stable plasma exposure across the dosing interval, which is associated with better gastrointestinal tolerability than less stable formulations that produce sharp peaks and troughs.

In the Phase 2 obesity trial of 469 participants, CT-388 produced up to 22.5% placebo-adjusted body weight reduction at 48 weeks at the highest dose. The weight-loss curve had not yet plateaued at the end of the trial, suggesting further reductions might be achievable with longer dosing. Roche acquired Carmot Therapeutics in late 2024 specifically to obtain CT-388, positioning it as their lead anti-obesity asset competing directly against tirzepatide and the next-generation Lilly and Novo Nordisk pipeline.

Ecnoglutide is a long-acting GLP-1 receptor agonist engineered for once-weekly subcutaneous dosing using a structural design distinct from albumin-binding (semaglutide) or PEGylation. The molecule incorporates extended-half-life modifications that resist DPP-4 enzymatic degradation while maintaining high-affinity binding and full agonist activity at the GLP-1 receptor.

Receptor activation produces the standard GLP-1 pharmacology: glucose-dependent insulin secretion from pancreatic beta cells, suppression of glucagon release from alpha cells, slowed gastric emptying via vagal signalling, and central appetite suppression through hypothalamic and brainstem GLP-1 receptors. The clinical profile in Chinese Phase 3 trials closely mirrors semaglutide — approximately 14-15% body weight loss in obesity studies and substantial HbA1c reductions in type 2 diabetes trials — positioning ecnoglutide as a regional alternative to Wegovy and Ozempic with potentially lower pricing.

Ecnoglutide reflects a broader trend of Chinese biotech companies developing GLP-1 receptor agonists for both domestic and international markets. Sciwind Biosciences has filed for regulatory approval in China and is pursuing international development pathways. The molecule is one of several Chinese-developed GLP-1s approaching commercial launch alongside mazdutide, retatrutide-class triple agonists in early Chinese development, and a wave of biosimilar semaglutide products expected as patents expire in major markets through the late 2020s.